This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
By This Author:
Page 4 of 593

Amgen Earnings Reveals Ugly Truth About Drug Pricing and Sales 'Growth'

By Adam Feuerstein

It's common for drug companies to raise the price of their existing products once or twice per year, every year. The price increases far outpace the rate of inflation.

10:18AM 04/22/15

Gilead Should Buy Vertex Pharma for $45B Now, Analyst Says

By Adam Feuerstein

Gilead Sciences should solve its long-term revenue cliff problem by acquiring Vertex Pharmaceuticals and its growing cystic fibrosis drug franchise for $45 billion, says Bernstein analyst Geoff Porges.

07:48AM 04/21/15

Juno, Kite CAR-T Stocks Fall on Disappointing Solid Tumor Data

By Adam Feuerstein

Shares of Juno Therapeutics and Kite Pharma are weak Monday following a lackluster showing for so-called CAR-T cellular therapies in solid tumors at a closely watched cancer conference this weekend.

10:22AM 04/20/15

Immune Cell Cancer Immunotherapy Passes First Safety Test in Solid Tumors

By Adam Feuerstein

The positive phase I safety study was conducted using a CAR-T therapy from Novartis and the University of Pennsylvania.

12:45PM 04/19/15

Merck Seeks Expanded Approval of Keytruda Immunotherapy to Treat Lung Cancer

By Adam Feuerstein

New Keytruda data presented for the first time shows an overall response rate of 19% and a median duration of response exceeding one year in lung cancer patients.

08:30AM 04/19/15

Biotech Stock Mailbag: Bluebird's Sickle Cell Data, Ariad's Faux Suitors, XBiotech Blech

By Adam Feuerstein

Biotech columnist Adam Feuerstein answers readers' questions about health care.

05:59AM 04/17/15

If SpaceX CEO Musk was Biotech CEO, Rocket's 'Landing' Big Win

By Adam Feuerstein

In which Musk learns how to put a happy spin on failure from biotech CEOs.

09:07AM 04/16/15

Cancer Immunotherapy Remains Hot as Aduro Biotech Doubles in Value On IPO Debut

By Adam Feuerstein

Aduro Biotech shares doubled in value Wednesday following a successful initial public offering -- another sign that investor demand for cancer immunotherapy stocks remains strong.

11:35AM 04/15/15

Gilead Sciences Sparks Analyst Dispute Over Hep C Forecasts

By Adam Feuerstein

The bull and bear cases for Gilead's first-quarter earnings hinge on discounts applied to prices of hepatitis C drug Harvoni and Sovaldi.

09:46AM 04/14/15

Advaxis Shares Rise Ahead of Aduro's Rival Cancer Immunotherapy IPO

By Adam Feuerstein

Advaxis' market value is half as large as competitor Aduro Biotech, which is expected to price its initial public offering on Thursday.

08:43AM 04/14/15

Page 4 of 593

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV


DOW 18,232.02 -53.72 -0.29%
S&P 500 2,126.06 -4.76 -0.22%
NASDAQ 5,089.3620 -1.4320 -0.03%

Brokerage Partners

Top Rated Stocks Top Rated Funds Top Rated ETFs